Company / Cash & Equivalents
PTC Therapeutics, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$984.6M
FY2025
5-year range
$189.7M / $984.6M
FY2021-FY2025
Trend
+26.3%
vs FY2024
Sector context
#20 of 207
Health Care
What the data says
Among 207 Health Care companies, PTC Therapeutics, Inc. is in the top 10% for cash & equivalents. Cash & Equivalents has increased for 4 consecutive years, from $190M in FY2021 to $985M in FY2025.
Based on SEC 10-K filings.
$985M in FY2025 with a 5-year CAGR of +36.4%. Top quartile in the Health Care sector.
Improved from $594M to $985M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +52.1%
- 5-Year CAGR
- +36.4%
- 10-Year CAGR
- -
Sector benchmark
Top 10% in Health CareTop 10% of 207This company $984.6M Sector average $669.5M
▼
+47.1% above sector average
Key checks
Key Insights
- PTC Therapeutics, Inc.'s cash & equivalents has grown for 4 consecutive years.
- 5-year CAGR of +36.4%, indicating consistent growth.
- In FY2025, cash & equivalents increased 26.3% year-over-year.
- Ranks #20 out of 207 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.95 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $984.6M | +26.3% |
| FY2024 | $779.7M | +31.3% |
| FY2023 | $594.0M | +112.3% |
| FY2022 | $279.8M | +47.5% |
| FY2021 | $189.7M | -9.1% |
| FY2020 | $208.8M | -27.5% |
| FY2019 | $288.0M | +69.9% |
| FY2018 | $169.5M | +51.6% |
| FY2017 | $111.8M | +91.7% |
| FY2016 | $58.3M | +0.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026